Cohen & Steers, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cohen & Steers, Inc. (NYSE: CNS) is an asset management firm specializing in real assets and alternative investments. The company offers a diverse range of products including closed-end funds, exchange-traded funds (ETFs), mutual funds, and separately managed accounts focused on real estate securities, infrastructure equities, preferred securities, utilities, and commodities; it also provides sub-advisory services and model portfolios to institutional and retail investors worldwide. Cohen & Steers operates primarily in the United States, Europe, and Asia, serving institutional clients such as pension funds, endowments, and sovereign wealth funds, as well as individual investors through intermediary channels. Founded in 1986 and headquartered in New York City, the firm manages approximately $85 billion in assets under management as of late 2025, with key subsidiaries including Cohen & Steers Capital Management, Inc.. In recent developments, Cohen & Steers launched several new ETFs in 2024 and 2025, including the Cohen & Steers Real Estate Securities and Utilities ETF and expanded its infrastructure-focused offerings to capitalize on global energy transition trends; the company also completed a strategic partnership with a major European pension fund in mid-2025 to enhance distribution of its alternative strategies across the region. Additionally, Cohen & Steers raised $500 million through a new closed-end fund issuance in Q3 2025 targeting U.S. infrastructure debt, marking its largest such offering in two years, and announced the acquisition of a boutique preferred securities manager to bolster its fixed-income alternatives platform. These moves reflect the firm's ongoing expansion into high-growth segments amid rising demand for real asset diversification.
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Cohen & Steers Income Opportunities REIT, Inc. Acquires Sprouts-Anchored Shopping Center
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Cohen & Steers Real Assets Strategies Now Available in South Africa
Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
Cohen & Steers Appoints Amit Muni as Chief Financial Officer
Cohen & Steers Announces Strategic Partnership with J.P. Morgan to Expand Access to Short Duration Hybrid Credit SICAV Strategy
Cohen & Steers Announces Strategic Partnership with J.P. Morgan to Expand Access to Short Duration Hybrid Credit SICAV Strategy
Cohen & Steers Announces Strategic Partnership with J.P. Morgan to Expand Access to Short Duration Hybrid Credit SICAV Strategy
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
Cohen & Steers Income Opportunities REIT, Inc. Acquires Shopping Center in Charlotte, North Carolina
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for April 2026